---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038523"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2023-10-27T23:59:59+00:00"
generated_at: "2026-06-09T07:07:36.463391+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics implements 1-for-25 reverse stock split to meet Nasdaq minimum bid price

## Summary
- Reverse stock split at 1:25 ratio effective October 25, 2023; shares reduced from ~29.9M to ~1.2M.
- Common stock began trading on post-split basis on Nasdaq under same ticker VVOS on October 27, 2023.
- No fractional shares issued; fractional shares rounded up to nearest whole share.
- Split approved by board under stockholder authority granted at 2023 Annual Meeting on September 22, 2023.
- Company aims to satisfy $1.00 minimum bid price requirement for continued Nasdaq listing under Rule 5550(a)(2).

## SEC filing metadata
- accession: 0001493152-23-038523
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2023-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/0001493152-23-038523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038523
- JSON: https://secwatch.observer/filing/0001493152-23-038523.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038523.txt

## Key facts
- Governance Changes
  Vivos Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-25 reverse stock split (effective 2023-10-25).
  - Change: charter amendment
  - Effective: 2023-10-25
  source text: On October 25, 2023, Vivos Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation with the Secretary of State of Delaware (the “ Certificate of Amendment ”) to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”) at a ratio of 1-for-25 (the “ Reverse Stock Split ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/0001493152-23-038523-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.